Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Timolol
Drug ID BADD_D02219
Description Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Indications and Usage Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure.[L6724,L6727] In certain cases, timolol is used in the prevention of migraine headaches.[A179530,L6742]
Marketing Status approved
ATC Code C07AA06; S01ED01
DrugBank ID DB00373
KEGG ID D00378; D08600
MeSH ID D013999
PubChem ID 33624
TTD Drug ID D05UVD
NDC Product Code 82584-001; 82584-002; 76478-001; 17478-189; 76478-002
UNII 817W3C6175
Synonyms Timolol | Timolol Maleate | Timolol Maleate, (1:1) Salt | (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol | 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- | Timoptic | Timoptol | Timacar | Timolol Hemihydrate | Blocadren | L-714,465 | L 714,465 | L714,465 | MK-950 | MK 950 | MK950 | Optimol
Chemical Information
Molecular Formula C13H24N4O3S
CAS Registry Number 26839-75-8
SMILES CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual acuity reduced06.02.10.012; 17.17.01.0110.000150%
Visual field defect17.17.01.001; 06.02.07.0030.000100%Not Available
Visual impairment06.02.10.0130.000391%Not Available
Vital dye staining cornea present13.07.04.010--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Foreign body sensation in eyes06.01.01.0060.000221%Not Available
Conjunctival hyperaemia06.04.01.0040.000100%Not Available
Haemodynamic instability24.03.02.0060.000100%Not Available
Eyelid margin crusting06.04.04.005; 23.03.03.0290.000512%Not Available
Eye pruritus06.04.05.0060.000271%Not Available
Ocular discomfort06.08.03.0080.000221%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.010--Not Available
Serositis08.01.05.006--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Sensation of foreign body08.01.09.002--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene